<DOC>
	<DOC>NCT00656890</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of the MDX-1100 regimen in subjects with active Ulcerative colitis(UC) and determine the response rate at day 57 in patients administered MDX-1100.</brief_summary>
	<brief_title>A Study of MDX-1100 in Subjects With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Subjects with active UC on either 5ASA,corticosteroids,azathioprine(AZA) and or/6mercaptopurine(6MP); Mayo score of 6 to 10 points with moderate to severe disease on endoscopy Subjects on the following medications; 1. prednisolone â‰¤ 20 mg daily (or equivalent) (dose must be stable for at least 2 weeks prior to study drug administration) 2. 5ASA (dose must be stable for at least 4 weeks prior to study drug administration) 3. AZA or 6MP (dose must be stable for at least 3 months prior to study drug administration) 4. Rectal steroids or 5ASA (must have been stable for at least 4 weeks prior to study drug) AntiTNF therapy within 8 weeks before study drug administration Contraindication to colonoscopy or sigmoidoscopy Primary or secondary immunodeficiency Autoimmune disease besides UC, with the exceptions of Sjogren's syndrome or hypothyroidism History of malignancy, excluding adequately treated and cured basal or squamous cell of the skin, or cervical carcinoma in situ Evidence of acute or chronic infection Clinically significant disease requiring medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>ulcerative colitis, rectal bleeding</keyword>
</DOC>